Clinical trials have shown Ronapreve – a mix of two lab-produced antibodies – to reduce the risk of hospitalisation or death for at-risk adults with mild to moderate covid by 70%. Usually given as an infusion or injection, Ronapreve works by attaching to the corona virus spike protein, stopping it getting into cells and causing […]
